The global protein binding assay market size was USD 374.06 million in 2020 and is expected to register a CAGR of 10.8% during the forecast period. Increasing focus on new drug discovery and development processes and rapid developments in pharmaceutical and biotechnological industries are primary factors fueling global protein binding assay market revenue growth.
Protein binding assay methods aid in quantifying binding of small molecule drug candidates to plasma proteins. These methods are widely applied in drug discovery and manufacturing processes. The extent of drug binding to plasma proteins, which are determined by measuring free active fraction, has a significant effect on the pharmacodynamics and pharmacokinetics of a drug. Protein binding assays are crucial in estimating drug-binding ability of various macromolecules in the early stages of drug discovery as well as in clinical trials. In this process, equilibrium dialysis technology is widely used. Moreover, these assays help in detecting target molecules, along with providing critical information regarding the properties of biologics and therapeutics. These factors are expected to support revenue growth of the market going ahead.
The binding of drug substances to plasma proteins is a highly relevant parameter in drug discovery as it directly affects plasma half-life, volume of distribution, and concentration of free compound available for interaction with the target protein. Moreover, high concentration of proteins in plasma and propensity of various drug candidates to bind to them have necessitated drug development groups to recognize the importance of Plasma Protein Binding (PPB) in modulating the concentration of an effective drug at pharmacological target sites. This is increasing demand for protein bonding assay methods, thus, contributing to revenue growth of the market. Additionally, increasing drug making activities by pharmaceutical and biotechnology companies in different regions globally are other primary factors driving revenue growth of the market. The trend is increasingly propelled by rising demand for novel drugs and advanced drug therapies for various chronic and hard-to-treat diseases. Furthermore, rising number of drug candidates in pipeline is a significant factor augmenting the need for better protein binding assays, which is further accelerating market revenue growth. Global protein binding assays market revenue has increased at an exponential rate owing to increasing need for optimization in drug discovery costs to avoid costly drug failures.
Request a Sample@ https://qyresearchmedical.com/sample/118921
Protein binding assays have not been utilized to their full potential in the past years due to various limitations associated with existing assay technologies and limited availability of clinical expertise in designing binding experiments. Moreover, rapid development of silico-based prediction models is another factor expected to retrain market revenue growth during the forecast period. Other factors, such as lack of information & skills related to the usage of protein binding assays worldwide and rising concerns associated with the technology available that is to be used in combination with various products, are predicted to further hinder market revenue growth.
Based on technology, the equilibrium dialysis segment is expected to register the highest revenue share in the global market during the forecast period. Equilibrium dialysis is considered as the most effective method for evaluating drug-protein binding. Various advantages of equilibrium dialysis including high accuracy, low cost, and reliability are attributed to the high revenue share of the segment. Moreover, the workflow of equilibrium dialysis is simple, which makes the technology a preferred choice to determine the protein binding capability of a drug compound being studied. This is further contributing to revenue growth of this segment.
End Use Outlook:
Based on end use, the pharmaceutical & biotechnology companies segment has emerged as the dominant segment in terms of revenue share in the market. Segment growth is attributed to high investments by major companies in global pharmacy production along with significantly high contribution on preclinical testing stages of drug discovery. Additionally, the industry is marked by robust presence of prominent, players including Roche and Merck that are engaged in R&D activities for maintaining their market position. Moreover, a large number of new CROs focused on manufacturing therapeutics are entering the market for capitalizing on potential avenues in the biopharmaceutical industry. These factors are expected to drive revenue growth of this segment.
The North America market is expected to account for largest revenue share in the global protein binding assay market going ahead. Presence of leading pharmaceutical and biotechnology companies, well-established pharmaceutical industry, and high R&D investments in North America are some of the primary factors fueling revenue growth of the regional market. Moreover, other factors such as high R&D investments and increasing drug development activities are also supporting revenue growth of North American market.
Asia Pacific market revenue is expected to increase significantly in the global market over the forecast period owing to various initiatives undertaken by regulatory agencies to revolutionize drug discovery and their manufacturing programs in countries in the region.
Companies considered and profiled in this market study
Charles River; Thermo Fisher Scientific, Inc.; Sovicell GMBH; GE Healthcare; Absorption Systems LLC; Eurofins Scientific; Creative Biolabs; 3B Pharmaceuticals; Evotec (Cyprotex); and Bioduro.
Market players are engaging in various strategic initiatives for strengthening protein binding assays portfolio and expanding market footprint. Some of the strategies deployed include agreements, collaborative models, business expansions, and product developments.
- In March 2018, Thermo Fisher signed an agreement with Montreal Neurological Institute, under which the institute generated cell lines by using Fisher’s antibodies and protein binding assays to study different types of neurodegenerative diseases.
Segments Covered in the report
This report forecasts revenue growth at a global, regional & country level and provides an analysis of the market trends in each of the sub-segments from 2019 to 2030.
For the purpose of this report, Reports and Data has segmented the global protein binding assays market on the basis of technology, end use, and region:
Protein Binding Assays Market Report Scope
Segments covered By Technology Outlook, End Use Outlook, Regional Outlook
By Technology Outlook
Other technologies (chromatography (size exclusion/gel filtration), surface plasmon resonance, and transil partitioning)
By End Use Outlook
Pharmaceutical & biotechnology companies
Contract Research Organizations (CROs)
Other end users (academic institutes and government organizations)
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/118921/1500
You can place an order or ask any questions, please feel free to contact firstname.lastname@example.org | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: